Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting {beta}2-adrenoceptor agonist, with formoterol in patients with asthma

Conclusions:
AZD3199 480 µg and 1920 µg produced 24-hour bronchodilation. At comparable peak bronchodilator effect, AZD3199 was associated with a lower level of systemic side effects than formoterol. AZD3199 was well tolerated, with no safety concerns identified to preclude further investigation.

ClinicalTrials.gov study identifier:
NCT00736489

Source: Therapeutic Advances in Respiratory Disease - September 19, 2013 Category: Respiratory Medicine Authors: Bjermer, L., Rosenborg, J., Bengtsson, T., Lotvall, J. Tags: Original Research Source Type: research